These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22875603)

  • 1. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines.
    Plikaytis BD; Stella M; Boccadifuoco G; DeTora LM; Agnusdei M; Santini L; Brunelli B; Orlandi L; Simmini I; Giuliani M; Ledroit M; Hong E; Taha MK; Ellie K; Rajam G; Carlone GM; Claus H; Vogel U; Borrow R; Findlow J; Gilchrist S; Stefanelli P; Fazio C; Carannante A; Oksnes J; Fritzsønn E; Klem AM; Caugant DA; Abad R; Vázquez JA; Rappuoli R; Pizza M; Donnelly JJ; Medini D
    Clin Vaccine Immunol; 2012 Oct; 19(10):1609-17. PubMed ID: 22875603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets.
    Law DK; Lefebvre B; Gilca R; Deng S; Zhou J; De Wals P; Tsang RS
    BMC Microbiol; 2015 Jul; 15():143. PubMed ID: 26204985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
    Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
    Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal Antigen Typing System (MATS)-Based
    Rajam G; Stella M; Kim E; Paulos S; Boccadifuoco G; Serino L; Carlone G; Medini D
    mSphere; 2017; 2(6):. PubMed ID: 29152576
    [No Abstract]   [Full Text] [Related]  

  • 6. Meningococcal Antigen Typing System (MATS): A Tool to Estimate Global Coverage for 4CMenB, a Multicomponent Meningococcal B Vaccine.
    Boccadifuoco G; Brunelli B; Mori E; Agnusdei M; Gianfaldoni C; Giuliani MM
    Methods Mol Biol; 2019; 1969():205-215. PubMed ID: 30877679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland.
    Waśko I; Hong E; De Paola R; Stella M; Moschioni M; Taha MK; Skoczyńska A
    Vaccine; 2016 Jan; 34(4):510-515. PubMed ID: 26686998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.
    Abad R; Biolchi A; Moschioni M; Giuliani MM; Pizza M; Vázquez JA
    Clin Vaccine Immunol; 2015 Apr; 22(4):357-60. PubMed ID: 25630407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries.
    Abad R; Medina V; Stella M; Boccadifuoco G; Comanducci M; Bambini S; Muzzi A; Vázquez JA
    PLoS One; 2016; 11(3):e0150721. PubMed ID: 26950303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
    Pajon R; Lujan E; Granoff DM
    Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.
    Lucidarme J; Comanducci M; Findlow J; Gray SJ; Kaczmarski EB; Guiver M; Vallely PJ; Oster P; Pizza M; Bambini S; Muzzi A; Borrow R
    Clin Vaccine Immunol; 2010 Jun; 17(6):919-29. PubMed ID: 20375242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bexsero: a multicomponent vaccine for prevention of meningococcal disease.
    Gorringe AR; Pajón R
    Hum Vaccin Immunother; 2012 Feb; 8(2):174-83. PubMed ID: 22426368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 15. Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway.
    Holst J; Comanducci M; Bambini S; Muzzi A; Comandi S; Oksnes J; DeTora L; Pizza M; Rappuoli R; Caugant DA
    Vaccine; 2014 May; 32(23):2722-31. PubMed ID: 24631075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
    Rossi R; Beernink PT; Giuntini S; Granoff DM
    Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Variation of NadA in Invasive Neisseria meningitidis Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine.
    Green LR; Lucidarme J; Dave N; Chan H; Clark S; Borrow R; Bayliss CD
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29950334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.
    Donnelly J; Medini D; Boccadifuoco G; Biolchi A; Ward J; Frasch C; Moxon ER; Stella M; Comanducci M; Bambini S; Muzzi A; Andrews W; Chen J; Santos G; Santini L; Boucher P; Serruto D; Pizza M; Rappuoli R; Giuliani MM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19490-5. PubMed ID: 20962280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.
    Medini D; Stella M; Wassil J
    Vaccine; 2015 May; 33(23):2629-36. PubMed ID: 25882169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.